A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy

Epilepsy Research

Volumn 27, Issue 3, 1997, Pages 195-204

  Bill, Pierre Alfred ^a   Vigonius, Ulf ^b   Pohlmann, Harald ^c   Guerreiro, Carlos Alberto M ^d   Kochen, Silvia ^e   Saffer, David ^f   Moore, Alan ^c  

^a Wentworth Hospital   (South Africa)

^b Novartis Sverige AB Vastra Frolunda   (Sweden)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e HOSPITAL RAMOS MEJÍA   (Argentina)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Long term treatment; Monotherapy; Oxcarbazepine; Phenytoin

Indexed keywords

ANTICONVULSIVE AGENT; OXCARBAZEPINE; PHENYTOIN;

ACNE; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EPILEPSY; FEMALE; FOCAL EPILEPSY; GRAND MAL EPILEPSY; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TITRIMETRY; TREATMENT OUTCOME; TREMOR; VERTIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN;

EID: 0030805745     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(97)00024-7     Document Type: Article

References (14)

1. Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol 1990;3(1):21-30.
2. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992;43:873-88.
3. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanism of action. Epilepsia 1994;35(5):S47-50.
4. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3(1):70-6.
5. Reinikainin KJ, Keraenen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987;1(5):284-9.
6. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L. Therapeutic experiences with 947 epileptic outpatients in oxcarbazepine treatment. Acta Neurol Scand 1993;87(3):224-7.
7. for the OT/F10 Study Group, Vigonius U, Moore A, Kraemer G, Canger R, Deisenhammer E, Schiwy W. Oxcarbazepine: Results of a clinical trial designed to assess the feasibility of a twice-daily administration. Epilepsia Abstr 1995;36(3):S119.
8. Dam M. Drug therapy for different types of seizures. In: Sillanpää M, Johannessen SI, Blennow G, Dam M, editors. Paediatric Epilepsy. Wrightson Biomedical, 1990:269-278.
9. Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. Lancet -4.
10. The Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised clinical and electroencephalographic classification of epileptic seizures, Epilepsia 22 (4) (1981) 489-501.
11. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
12. Sander JWAS. Some aspects of prognosis in epilepsies. Epilepsia 1993;34:1007-16.
13. Trileptal Summary of Product Characteristics, Ciba-Geigy, Basel, March 24 1993.
14. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carmazepine and oxcartherapy. Epilepsia 1994;35(1):181-8.